These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 30145588

  • 1. Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: A 25-Year Follow-Up Study.
    Johansson L, Kern S, Zetterberg H, Blennow K, Börjesson-Hansson A, Rosengren L, Guo X, Skoog I.
    Dement Geriatr Cogn Disord; 2018; 46(1-2):90-99. PubMed ID: 30145588
    [Abstract] [Full Text] [Related]

  • 2. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C.
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [Abstract] [Full Text] [Related]

  • 3. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 4. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Jan; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 5. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 6. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM.
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [Abstract] [Full Text] [Related]

  • 7. Amyloid β42 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death.
    Ribbe M, Kern S, Börjesson Hansson A, Östling S, Zetterberg H, Blennow K, Skoog I.
    Dement Geriatr Cogn Disord; 2019 Sep; 47(1-2):114-124. PubMed ID: 30970371
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F.
    J Alzheimers Dis; 2016 Sep; 51(4):1069-83. PubMed ID: 26923009
    [Abstract] [Full Text] [Related]

  • 9. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [Abstract] [Full Text] [Related]

  • 10. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
    Höglund K, Kern S, Zettergren A, Börjesson-Hansson A, Zetterberg H, Skoog I, Blennow K.
    Transl Psychiatry; 2017 Jan 10; 7(1):e995. PubMed ID: 28072416
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.
    Hoscheidt SM, Starks EJ, Oh JM, Zetterberg H, Blennow K, Krause RA, Gleason CE, Puglielli L, Atwood CS, Carlsson CM, Asthana S, Johnson SC, Bendlin BB.
    J Alzheimers Dis; 2016 Apr 12; 52(4):1373-83. PubMed ID: 27079723
    [Abstract] [Full Text] [Related]

  • 15. Cerebrospinal fluid biomarkers of Alzheimer's disease in Chinese patients: a pilot study.
    Shea YF, Chu LW, Zhou L, Li WM, Lin OY, Chan MN, Xu A, Wong R, Ho TY, Liu KW, Ha J, Daniel TW, Song YQ, Lam KS.
    Am J Alzheimers Dis Other Demen; 2013 Dec 12; 28(8):769-75. PubMed ID: 24085246
    [Abstract] [Full Text] [Related]

  • 16. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M, Thomas C, Boedeker S, Kreisel S, Driessen M, Beblo T, Ohrmann P, Toepper M.
    Exp Gerontol; 2016 Jan 12; 73():107-13. PubMed ID: 26585048
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X, Shi H, Hou L, Zhong X, Chen X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chen J, Fang Y, He H, Ning Y.
    Eur J Neurol; 2015 May 12; 22(5):853-8. PubMed ID: 25707998
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.